---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Budget impact model discussion"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Budget impact model discussion. Topics: Company statements on pricing, coverage, and reimbursement of ficerafusp alfa; Data sources recommended for budget impact inputs. 3 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics/budget-impact-model-discussion"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Budget impact model discussion

<a id="heading-4.2.7"></a>

## 4.2.7 Budget impact model discussion

<a id="topic-4.2.7-1"></a>

### Summary

Task force good-practice guidance on budget impact analysis lists the key elements of a budget impact analysis as the size of the eligible population, the current and expected treatment mix, the cost of each mix, and changes in condition-related costs, and recommends the perspective of the specific decision maker, data from the decision maker's own population where possible, and presentation as a series of scenario analyses. For ficerafusp alfa, two inputs are not yet available: a price, and efficacy from randomized evidence. Results reported to date come from a nonrandomized, open-label phase 1/1b trial, and Bicara expects an interim analysis of the randomized FORTIFI-HN01 trial in mid-2027.

The population inputs in this report differ by source and are candidates for scenario ranges. The estimated HPV-negative share of recurrent or metastatic disease is 80% in Bicara's Form 10-K; in a U.S. real-world first-line cohort, 60.4% had non-HPV associated disease and 7.0% had unknown HPV status or primary site, and in a U.S. real-world cohort of first-line pembrolizumab recipients, 258 participants (39.9%) were HPV-negative and 155 (24.0%) equivocal or unknown. Bicara states that up to 30% of patients develop a recurrence or metastases after initial treatment for advanced HNSCC; Hanna et al. (2026) state that approximately 50% of those with locally advanced HNSCC have recurrence or metastasis after initial therapy; of 2,207 U.S. participants, 32.7%. Because the pivotal population requires PD-L1 CPS ≥1, testing rates bear on the identifiable population: of 2,207 U.S. participants, 32.7% received PD-L1 testing before first-line therapy and 50.0% were never tested.

On costs, pembrolizumab is given in both arms of FORTIFI-HN01, and ficerafusp alfa is given weekly until disease progression or unacceptable toxicity, while pembrolizumab is given for up to 35 cycles. FORTIFI-FLEX is evaluating a 12-week loading phase of 1500 mg weekly followed by 2250 mg every 3 weeks, which would change the number of administrations if adopted. Bicara states that third-party payers “may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/); [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/); [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12099209/); [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/); [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/); [Hanna et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39754998/); [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129); [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163); [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-4.2.7-2"></a>

### Company statements on pricing, coverage, and reimbursement of ficerafusp alfa

> “Even if ficerafusp alfa achieves marketing approval, it may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness.”
> “The availability of coverage and the adequacy of reimbursement by governmental healthcare programs including but not limited to Medicare and Medicaid, private health insurers and other third-party payors, are essential for most patients to be able to afford prescription medications such as ficerafusp alfa or any future product candidates, if approved.”
> “Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-4.2.7-3"></a>

### Data sources recommended for budget impact inputs

> “Data sources for the BIA should include published clinical trial estimates and comparator studies for the efficacy and safety of the current and new interventions as well as the decision maker's own population for the other parameter estimates, where possible.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
